Background Vortioxetine is a novel multimodal compound that has recently been approved
by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin …

Background: Vortioxetine was approved by the US Food and Drug Administration (FDA) in
September 2013 for treating major depressive disorder (MDD). Thus far, a number of …

The efficacy and safety of vortioxetine, an antidepressant approved for the treatment of
adults with major depressive disorder (MDD), was studied in 11 randomized, double-blind …

Objective We aimed to compare the efficacy, acceptability, and tolerability of vortioxetine in
the treatment of Major Depressive Disorder (MDD) in adults. Method We searched PubMed …

Aim This study assessed the efficacy and safety of vortioxetine in adults with major
depressive disorder. Methods In this double‐blind, placebo‐controlled study, 600 patients …

Abstract Objective: Vortioxetine (Lu AA21004) is an investigational antidepressant. In vitro
studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5 …

Objective: To conduct a meta-analysis of studies of vortioxetine in adults with major
depressive disorder (MDD). Data Sources: Abstracts were identified using PubMed by cross …

Objective This meta-analysis assessed the efficacy and safety of 5 mg/day vortioxetine
compared to placebo for adult major depressive disorder. Methods We performed a meta …

Introduction Major depressive disorder (MDD) is a highly prevalent and burdensome
condition. This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine …

Aim Major depressive disorder (MDD) is a prevalent psychiatric condition and vortioxetine
offers promising antidepressant effects due to its unique pharmacological profile. However …